亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

成都云希化工有限公司  

美容肽,多肽,美容原料,定制肽,醫藥中間體

搜索
新聞中心
  • 暫無新聞
產品分類
聯系方式
  • 聯系人:陳
  • 電話:19150309904
  • 郵件:aileen@youngshechem.com
  • 微信:19150309904
  • QQ:1398029096
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > Vapreotide伐普肽103222-11-3
Vapreotide伐普肽103222-11-3
單價 10.00 / g對比
銷量 暫無
發貨 四川成都市付款后3天內
庫存 1000g起訂1g
品牌 成都云希
CAS號 103222-11-3(net), 849479-74-9(acetate)
外觀 白色粉末
過期 長期有效
更新 2021-07-23 15:32
 
詳細信息

Name:Vapreotide Acetate

Cas No: 103222-11-3(net), 849479-74-9(acetate)

Formula: C57H70N12O9S2

Molecular: 1131.371

Sequence: D-Phe-(Cys-Tyr-D-Trp-Lys-Val-Cys)-Trp-NH2

Also know as Octastatin,docrised. BMY-41606, RC-160, Sanvar, Octastatin

 

產品參數:

 

INCI名稱:伐普肽

形狀:白色粉末

PH:無

純度:95%

儲存條件:2~8℃密封避光儲存,長期存儲建議零下15~20℃冷藏最佳

安全性:無重金屬,無皮膚及眼刺激

包裝規格:1/

注意:本品為科研原料,不建議用于人體

 

©2025 成都云希化工有限公司 版權所有   技術支持:化工網   訪問量:40946  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |